Drugs / CI-1040
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00033384 | Feb 2002 → Nov 2003 | breast cancer, colorectal cancer, lung cancer, malignant pancreatic neoplasm | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT00034827 | Jan 2002 → May 2003 | breast neoplasm, colorectal neoplasm, non-small cell lung carcinoma, pancreatic neoplasm | Pfizer | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CI-1040 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00033384 ↗ |
| Known as | PD-18435 | ChEMBL registry synonym — accepted as the source's own label CHEMBL105442 ↗ |
| Known as | PD-184352 | ChEMBL registry synonym — accepted as the source's own label CHEMBL105442 ↗ |
| Action | Inhibit | “CI-1040 may stop the growth of tumors by blocking the enzymes necessary for cancer cell growth” NCT00033384 ↗2“Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL105442 ↗ “Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL105442 ↗ |
| Modality | Small molecule | — CHEMBL105442 ↗ |
| Route | Oral | “Patients receive oral CI-1040 twice daily on days 1-21.” NCT00033384 ↗ |
| Target | MAP2K1 | “Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL105442 ↗ |
| Target | MAP2K2 | “Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL105442 ↗ |